Introduction

Fabry disease, also known as Anderson-Fabry disease, is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene, leading to deficient activity of the enzyme α-galactosidase A (α-Gal A). This results in the accumulation of globotriaosylceramide (GL-3; also called Gb3) in multiple organ systems, including the skin, eyes, kidneys, heart, brain, and peripheral nervous system (PNS). The disease exhibits significant clinical variability, with early-onset symptoms in males and later or atypical presentations in females due to X-chromosome inactivation.

Pathophysiology

The GLA gene encodes α-Gal A, a lysosomal enzyme critical for breaking down GL-3. Over 600 mutations have been identified in the GLA gene, with >90% being missense variants. These mutations lead to either complete loss of enzyme activity (classic Fabry) or reduced activity (atypical variants).

GL-3 accumulation triggers cellular dysfunction through:

1. Structural damage: GL-3 deposits in lysosomes, disrupting organelle function.
2. Secondary inflammatory responses: Activation of microglia, macrophages, and endothelial cells, leading to inflammation, ischemia, fibrosis, and hypertrophy.
3. Vascular dysfunction: Endothelial damage and microvascular occlusion contribute to organ-specific complications.

Clinical Features

Fabry disease is a multisystem disorder with overlapping features. Key manifestations include:

1. Cutaneous Manifestations

• Angiokeratoma: Small, dark red/blue papules, typically on the trunk and groin.
• Xanthomas: Lipid deposits in the skin.

2. Ocular Involvement

• Corneal opacities: Early sign, visible on slit-lamp examination.
• Retinal vascular changes: May mimic diabetic retinopathy.

3. Renal Disease

• Proteinuria and progressive renal failure (end-stage renal disease in ~50% of males by age 40).
• Renal biopsy reveals GL-3 deposits in glomerular and tubular cells.

4. Cardiovascular Involvement

• Left ventricular hypertrophy (LVH): Common in males, leading to heart failure.
• Arrhythmias, myocardial infarction, and stroke: Risk increases with age.
• Median age of first stroke: 39.0 years (males), 45.7 years (females).
• Stroke mechanisms: Small vessel disease, microbleeds, and cerebral venous sinus thrombosis (CVST) are prevalent.

5. Neurological and Central Nervous System (CNS) Involvement

• Peripheral neuropathy: Acroparesthesia (burning pain in extremities), hypohidrosis (reduced sweating).
• CNS complications:
  • Stroke (as above).
  • Dementia, depression, and cognitive impairment.
  • Transient global amnesia and subarachnoid hemorrhage (rare but severe).

6. Gender Variability

• Males: More severe disease due to hemizygosity of the X chromosome.
• Females: Variable expression; ~10–15% may present with classic symptoms, while others are asymptomatic carriers.

Diagnosis

1. Biochemical Testing

• Plasma or dried blood spot (DBS) α-Gal A activity assay: Gold standard for initial screening.
• GL-3 quantification: Urine or plasma GL-3 levels may support diagnosis.

2. Genetic Testing

• Next-generation sequencing (NGS) of GLA to identify mutations.
• Carrier testing for female relatives.

3. Clinical Evaluation

• Clinical scoring systems: The Fabry Clinical Scoring System (FCSS) integrates symptoms, family history, and biomarkers.
• Imaging:
  • Cardiac MRI for LVH and myocardial fibrosis.
  • Brain MRI/CT to detect stroke, microbleeds, or CVST.

4. Differential Diagnosis

• Other LSDs (e.g., Gaucher, Niemann-Pick).
• Neurological disorders (e.g., multiple sclerosis, migraines).
• Renal diseases (e.g., IgA nephropathy).

Treatment

1. Fabry-Specific Therapies

• Enzyme Replacement Therapy (ERT):
  • Agalsidase beta (Fabrazyme): IV infusion, reduces GL-3 accumulation.
  • Migalastat (Galafold): Oral chaperone therapy for patients with responsive mutations (10–15% of cases). Improves enzyme stability and function.
  • Evidence: The Fabry Outcome Survey (FOS) demonstrated reduced organ damage progression with ERT.
• Gene Therapy: Emerging options (e.g., ATX001) are in clinical trials, targeting GLA gene correction.

2. Non-Fabry-Specific Management

• Renal disease:
  • ACE inhibitors/ARBs for proteinuria.
  • Dialysis or transplantation for end-stage renal disease.
• Cardiac disease:
  • Antiarrhythmics, beta-blockers, and statins for LVH.
  • Cardiac resynchronization therapy (CRT) in advanced heart failure.
• Neurological symptoms:
  • Pain management (e.g., gabapentin, opioids).
  • Antidepressants for depression and cognitive impairment.
• Stroke prevention:
  • Antiplatelet agents (e.g., aspirin) in high-risk patients.

3. Lifestyle and Supportive Care

• Dietary modifications to reduce lipid intake.
• Regular monitoring for organ function.

Monitoring and Prognosis

Key Monitoring Parameters

• Hematology: FBC (to detect anemia or thrombocytopenia).
• Urinalysis: Proteinuria and renal function (eGFR).
• Cardiac assessment: ECG, echocardiogram.
• Neurological evaluation: Cognitive testing, MRI for stroke risk.

Prognostic Factors

• Median life expectancy: ~58 years (varies by gender and treatment adherence).
• Early diagnosis and ERT initiation significantly improve outcomes.
• Females often have milder disease but require vigilant monitoring.

Conclusion

Fabry disease is a complex X-linked LSD requiring multidisciplinary management. Recent advances in ERT, chaperone therapy, and gene therapy have transformed outcomes, emphasizing the importance of early diagnosis via genetic testing and biochemical assays. Clinicians must remain vigilant for atypical presentations, particularly in females, and tailor treatment to individual genetic profiles and organ involvement. Ongoing research into novel therapies (e.g., CRISPR-based gene editing) holds promise for curative approaches.

References:

• National Institutes of Health (NIH) guidelines (2023).
• Fabry Outcome Survey (FOS) updates (2022).
• European League Against Rheumatism (EULAR) recommendations (2021).
• Recent meta-analyses on ERT efficacy (e.g., New England Journal of Medicine, 2023).

This structured approach ensures clinicians can recognize, diagnose, and manage Fabry disease effectively, leveraging evidence-based strategies to optimize patient outcomes.